AFM13   Click here for help

GtoPdb Ligand ID: 10067

Synonyms: AFM 13 | AFM-13
Immunopharmacology Ligand
Compound class: Antibody
Comment: AFM13 is a tetravalent bispecific anti-CD30/CD16A tandem diabody that is constructed solely from Fv domains [1]. It is being developed by Affimed as a novel NK cell-engaging immuno-oncology therapeutic for the treatment of CD30-expressing malignancies. AFM13 simultaneously binds CD30 on Hodgkin's lymphoma cells and CD16A (FcγRIIIA) on NK cells, and acts to selectively recruit NK cells immune effector cells to destroy the cancer cells. AFM's mechanism of action differs from that of the anti-CD30 antibody-drug conjugate brentuximab vedotin, and it was found to be active in brentuximab vedotin-refractory patients in Phase 1 trial [2].
Click here for help
Bioactivity Comments
Cytotoxicity of AFM13 is CD30-dependent and it does not bind the CD16B isoform [1].
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CD30 Hs Antibody Binding 8.0 pKd - 1
pKd 8.0 (Kd 9.3x10-9 M) [1]
Description: Binding to CD30 determined in a competition assay on KARPAS-299 cells.
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Fc fragment of IgG receptor IIIa Primary target of this compound Hs Antibody Binding 9.1 – 9.4 pKd - 1
pKd 9.1 – 9.4 (Kd 8.4x10-10 – 3.9x10-10 M) [1]
Description: Binding to CD16a 158V and 158F proteins by SPR.